High activity oral preparation workshop located in Hequan Pharmaceutical Wuxi Base
Tablet Press Equipment
Shanghai, China, September 26, 2022 — Hequan Pharmaceutical, a global leader in contract research, development and manufacturing (CRDMO) for new drugs, today announced that its high-activity ( High Potency) oral preparation workshop was officially put into production, this important milestone marks the further improvement of Hequan Pharmaceutical’s preparation platform capabilities to better meet the growing needs of partners in the research and development and production of highly active drugs.
With the opening of the high-activity oral preparation workshop, Hequan Pharmaceutical can be a partner in the development of high-activity innovative drugs, providing services from API to preparation, from R&D to production, from preclinical to commercialized “one-stop, end-to-end” services. In addition, the company’s high-active API platforms are located in Changzhou base and Shanghai Jinshan base, which are relatively close to Wuxi base. The three sites will make full use of their geographical advantages to better leverage upstream and downstream synergies. Hequan Pharmaceutical will also open the first high-viability sterile injection workshop at its Wuxi base in the third quarter of 2023.
The Containment Performance Target (CPT) of the high-activity oral preparation workshop of Hequan Pharmaceutical Wuxi Base can reach the Occupational Exposure Limit (OEL) as low as nanogram level control Require. The workshop is equipped with various processes such as wet/dry granulation, tableting, coating and capsule filling, which can fully meet the needs of partners for different processes, and can support the production of high-efficiency active ingredient tablets and capsules, with an annual production capacity of 400 million Tablets and 200 million capsules.
Dr. Chen Minzhang, Co-CEO of WuXi AppTec and CEO of Hequan Pharmaceutical, said: “We are very pleased that our high-activity oral preparation workshop is officially put into operation, enabling the development of high-barrier preparations. .Hequan Pharmaceutical always attaches great importance to the various needs of partners in the development of new drugs, and fulfills the promise of empowering customers by enhancing the capabilities of the integrated CMC platform. In the future, we will continue to enhance the capabilities and scale of the empowerment platform to help More innovative drugs will come out as soon as possible to benefit the majority of patients.”
In recent years, Hequan Pharmaceutical has continued to improve its formulation platform capabilities to meet the diverse needs of global partners. In 2021, the company will acquire Bristol-Myers Squibb’s Couvet formulation production base in Switzerland to provide commercial production and packaging services for tablets and capsules. In addition, the Phase 1 project of the company’s Middletown formulation base in Delaware, USA is also under construction, and will provide customers with “one-stop” services from prescription development to clinical and commercial formulation production in the future.
About Hequan Pharmaceutical
Hequan Pharmaceutical is a subsidiary of WuXi AppTec with R&D and production bases in many places around the world. Hequan Pharma serves the life science industry and has excellent capabilities and technology platforms for R&D and production of innovative chemical drugs. As a global leader in contract research, development and manufacturing of new drugs (CRDMO), Hequan Pharmaceutical is committed to providing global partners with efficient, flexible and high-quality one-stop solutions to support products including small molecules, oligonucleotides Research and development and production of acids, peptides and various complex chemical conjugated drugs. For more information, please visit the company’s website: www.stapharma.com.cn